Antiangiogenic Agents
Drug	Target	General Mechanism of Action
AEE788	VEGFR-1 & -2, EGFR	Dual inhibitor of EGFR and VEGFR
Vandetanib (ZD6474)	VEGFR-2, EGFR, FGFR-1, RET	Dual inhibitor of EGFR and VEGFR
Axitinib (AG-013736)	VEGFR-1, -2 & -3, PDGFR-β, c-Kit	Inhibits VEGFR autophosphorylation, inhibits endothelial cell proliferation and survival
Sunitinib (SU11248)	VEGFR-1, -2 & -3, PDGFR-β, c-Kit	Inhibits endothelial cell proliferation and survival
Recentin (AZD2171)	VEGFR-1, -2 & -3, PDGFR-β, c-Kit	Inhibits VEGF-induced angiogenesis in vivo
Vatalanib (PTK787/ZK222584)	VEGFR-1, -2 & -3, PDGFR-β, c-Kit	Inhibits endothelial cell proliferation and survival
Sorafenib (BAY 43-9006)	VEGFR-2 & -3, Raf kinase, PDGFR-β, c-	Inhibits tumor and endothelial cell proliferation and survival
O-(chloro-acetyl-carbamoyl) (TNP-470/AGM-1470)	Kit, RET EC growth	Relatively specifically cytostatically inhibits endothelial cell growth (UI 8297716)
PX-866	PI3-Kinase	Inhibits PI-3-kinase pathway, cellular proliferation and survival
LY294002	PI3-Kinase	Inhibits PI-3-kinase pathway, cellular proliferation and survival
Wortmannin	PI3-Kinase	Inhibits PI-3-kinase pathway, cellular proliferation and survival
Bevacizumab (rhuMAb VEGF)	VEGF	Monoclonal antibody to VEGF
Volociximab	AAB1	targets AAB1, a component protein of α5β1
HuMV833	VEGF	recombinant humanized IgG4k monoclonal antibody targeting VEGF
“VEGF-trap” (AVE 0005)	VEGF	Fusion of human IgG1 Fc to extracellular domains of VEGFR-1 and VEGFR-2; binds VEGF
IMC-1121B (anti-VEGFR-2MAb)	VEGF-R2	IgG antibody targeting VEGFR-2
Endostatin	α5β1, αvβ3 & αvβ5	Interferes with migration and proliferation of endothelial cell
Tumstatin	αvβ3	Inhibits EC protein synthesis
Angiostatin	Integrin αvβ3	Competitively binds to integrins, inhibiting interaction with matrix ligands, interfering w/cell attachment and adhesion
Neovastat	MMPs	Inhibition of MMPs